Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - AILERON THERAPEUTICS INC | alrn-ex322_10.htm |
| EX-31.2 - EX-31.2 - AILERON THERAPEUTICS INC | alrn-ex312_8.htm |
| EX-31.1 - EX-31.1 - AILERON THERAPEUTICS INC | alrn-ex311_12.htm |
| EX-23.1 - EX-23.1 - AILERON THERAPEUTICS INC | alrn-ex231_7.htm |
| EX-10.27 - EX-10.27 - AILERON THERAPEUTICS INC | alrn-ex1027_815.htm |
| EX-10.26 - EX-10.26 - AILERON THERAPEUTICS INC | alrn-ex1026_814.htm |
| EX-4.3 - EX-4.3 - AILERON THERAPEUTICS INC | alrn-ex43_729.htm |
| 10-K - 10-K - AILERON THERAPEUTICS INC | alrn-10k_20191231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Aileron Therapeutics, Inc. (the “Company”) for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge on the date hereof:
|
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: March 30, 2020 |
|
/s/ Manuel C. Alves Aivado, M.D., Ph.D. |
|
|
|
Manuel C. Alves Aivado, M.D., Ph.D. |
|
|
|
President and Chief Executive Officer |